ImmunityBio Inc (NASDAQ: IBRX) is a clinical-stage biopharmaceutical company that develops and commercializes immunotherapy treatments for cancer and infectious diseases. Revenue is generated through commercialization of its approved product ANKTIVA, with the company relying on third-party contract manufacturers (CMOs), contract research organizations (CROs), and sales and marketing service providers to support operations. ImmunityBio depends on third and related parties for manufacturing, distribution, government price reporting, customer service, accounts receivable management, cash collection, and adverse event reporting, as disclosed in its 10-K filed February 23, 2026. The company is seeking incremental regulatory approvals for ANKTIVA internationally while running large-scale clinical trials for additional product candidates. As a commercial-stage company still heavily dependent on external partners and ongoing clinical programs, it carries material execution risk tied to regulatory timelines, manufacturing compliance with cGMP standards, and clinical trial adherence to GCP guidelines.

Revenue model

Product revenue from commercialization of ANKTIVA, its FDA-approved immunotherapy. Third-party service providers handle distribution, government price reporting, and cash collection on the company's behalf.

Products and services

ANKTIVA (approved immunotherapy product); additional oncology and infectious disease product candidates in clinical development.

Customers and end markets

Oncology and infectious disease end markets. Specific customer names, counts, or concentration data are not disclosed in the provided filing excerpts.

Value-chain role

Drug developer and commercial-stage biopharmaceutical company. Outsources manufacturing to CMOs, clinical trial execution to CROs and academic or medical institutions, and commercial services including distribution, government price reporting, and adverse event reporting to third-party and related-party vendors.

Geographic exposure

Pursuing international regulatory approvals for ANKTIVA, indicating a U.S. commercial base with international expansion underway. Specific geographic revenue breakdown is not disclosed in the provided filing excerpts.

Source: SEC 10-K, filed 2026-02-23

Industry: Biological Products, (No Diagnostic Substances) Peers: Arcus Biosciences Inc EQRx, Inc. Fate Therapeutics Inc IVERIC bio, Inc. Krystal Biotech Inc Recursion Pharmaceuticals Inc Prokidney Corp Twist Bioscience Corp Verve Therapeutics, Inc.